Abel Temeche Kassaw

Abel Temeche Kassaw

Auto-generated profile, based on publicly available information

Abel Temeche Kassaw

Department of Clinical Pharmacy, Pharmacy Education and Clinical Services Directorate, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2026 in Therapeutic Advances in Drug Safety
Verified
Journal Article
Open access
AKAbel Temeche Kassaw
Abel Temeche Kassaw
GYGetachew Yitayew
Getachew Yitayew
TZTigabu Eskeziya Zerihun
Tigabu Eskeziya Zerihun
ABAbaynesh Fentahun Bekalu
Abaynesh Fentahun Bekalu
SWSamuel Agegnew Wondm
Samuel Agegnew Wondm
SDSamuel Berihun Dagnew
Samuel Berihun Dagnew
Background: Drug-related problems (DRPs) are a significant concern in hospitalized patients. In Ethiopia, DRPs occur at a rate of 9.2 per 100 admissions and 9.4 per 1,000 patient days; however, pediatric-specific data are limited. Objective: This study assessed the magnitude, types, and predictors of DRPs and evaluated the acceptability of pharmacist-led interventions in pediatric intensive care units (PICUs) in Northwest Ethiopia. Design: A multicenter prospective interventional study Methods: All pediatric patients admitted to the PICU during the study period were consecutively enrolled. The study was conducted from January 1, 2025 to March 31, 2025 across four specialized hospitals, resulting in a total of 394 participants. DRPs were identified through medical record reviews, caregiver interviews, and direct bedside assessment by a clinical pharmacist. Each DRP was classified according to the Pharmaceutical Care Network Europe (PCNE) classification system version 8.01. Binary logistic regression was performed to identify independent predictors of DRPs. Results: Of the patients, 251 (63.7%) experienced at least one DRP, with 522 DRPs identified (mean 1.3 ± 0.8 per patient). The dominant domains were treatment effectiveness (54.6%) and treatment safety (30.3%), and 97.7% were deemed preventable. Drug and dose selection were the main causes (46.0% and 43.8%, respectively). Independent predictors included age 29 days–1 year (AOR = 2.2, 95% CI: 1.0–4.8), polypharmacy (⩾5 medications; AOR = 1.7, 95% CI: 1.0–2.8), multiple prescribers (AOR = 1.8, 95% CI: 1.1–2.9), prolonged ICU stay (⩾10 days; AOR = 2.4, 95%CI: 1.2–4.7), circulatory system disease (AOR = 3.5, 95% CI: 1.4–9.0), the use of anti-infectives (AOR = 5.0, 95% CI: 2.0–13.7), and antiepileptics medications (AOR = 2.1, 95% CI: 1.0–4.3) were independent predictors of DRPs. Conclusion: DRPs were common in PICU but predominantly preventable. Despite a modest mean number of DRPs per patient, the type and causes identified indicate opportunities for optimizing medication use. Younger age, polypharmacy, multiple prescribers, prolonged PICU stays, circulatory system disease, and specific drug classes were independent predictors. The high acceptance and effectiveness of pharmacist-led interventions underscore their crucial role in improving medication safety and optimizing pharmacotherapy in resource-limited intensive care settings.

4 November 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
DMDesalegn Addis Mussie
Desalegn Addis Mussie
TZTigabu Eskeziya Zerihun
Tigabu Eskeziya Zerihun
AKAbel Temeche Kassaw
Abel Temeche Kassaw
EMEsileman Abdela Muche
Esileman Abdela Muche
Objective: To ascertain the clinical impact, prevalence and associated determinants of delayed treatment intensification, defined as delaying the escalation of treatment plans for individuals with type 2 diabetes mellitus who fail to attain ideal glycaemic control, at the University of Gondar Comprehensive Specialised Hospital in Northwest Ethiopia. Design: A mixed-methods study. Setting: University of Gondar Comprehensive Specialised Hospital. Participants: 420 patients with type 2 diabetes mellitus with poor glycaemic control after the index date were included in this study. A simple random sampling technique was employed to select the required sample size. Data were collected retrospectively and entered into EpiData V.4.6 and exported to Stata V.14.2 for analysis. Method: Multivariable logistic regression was used to identify factors associated with delayed treatment intensification. A p value of 0.05 in the multivariable analysis was considered statistically significant. Qualitative data were collected through in-depth interviews with eight selected healthcare providers, and thematic analysis was undertaken to identify the underlying barriers to timely treatment intensification. Primary outcome: Delayed treatment intensification. Results: The prevalence of delayed treatment intensification was 51.4% (95% CI 46.6% to 56.2%), with a median delay of 14 months (IQR: 7.5–42 months) from the index date. Among those experiencing delayed treatment intensification, 43.1% developed new chronic diabetic complications, including retinopathy (18.1%), neuropathy (14.4%) and nephropathy (6.0%). Other complications (hypertension, stroke, heart failure and diabetic foot ulcer) accounted for 4.64% of the cases. Significant predictors of delayed treatment intensification included longer duration of diabetes (adjusted ORs (AOR) 1.68; 95% CI 1.13 to 2.5), presence of comorbidities (AOR 1.83; 95% CI 1.04 to 3.2) and use of cardioprotective medications (AOR 1.59; 95% CI: 1.04 to 2.43). The qualitative findings revealed additional barriers contributing to delayed treatment intensification, including financial limitations, insufficient patient awareness and non-adherence among patients. Additionally, healthcare provider-related factors, including professional fatigue and knowledge gaps, as well as health institution-related factors such as inadequate healthcare infrastructure. Conclusions: This study found a high prevalence of delayed treatment intensification (51.4%), associated with comorbidities, longer disease duration, low patient awareness, cardioprotective drug use and barriers related to the system and providers. To address these gaps, priorities should include strengthening patient education, scheduling regular reviews for high-risk patients and improving clinical decision support tools for timely treatment intensification. Enhancing healthcare infrastructure, such as medication supply and diagnostic services, and offering refresher training to reduce provider fatigue, are also crucial for improving the delivery of diabetes care.

14 March 2026 in Cancer Control
Verified
Journal Article
Open access
AKAbel Temeche Kassaw
Abel Temeche Kassaw
ETEphrem Tafesse Teferi
Ephrem Tafesse Teferi
GTGetachew Yitayew Tarekegn
Getachew Yitayew Tarekegn
TZTigabu Eskeziya Zerihun
Tigabu Eskeziya Zerihun
SWSamuel Agegnew Wondm
Samuel Agegnew Wondm
MBMekuanent Kassa Birarra
Mekuanent Kassa Birarra
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma and a leading cause of cancer-related mortality worldwide. Evidence on long-term survival and prognostic determinants remains limited, particularly among people living with HIV. This study evaluated survival outcomes and predictors of mortality among adults with DLBCL in Northwest Ethiopia. Methods: We conducted a multicenter retrospective cohort study of consecutively enrolled adults with newly histologically confirmed DLBCL diagnosed between August 1, 2020, and July 31, 2025, at three referral hospitals in Northwest Ethiopia. Patients were followed from diagnosis until death, loss to follow-up, or study end. Overall survival (OS) was estimated using the Kaplan–Meier method. Cox proportional hazard regression was used to identify independent predictors of mortality. Subgroup analyses were performed depending on HIV status. Statistical significance was set at P ≤0.05. Results: A total of 175 patients with DLBCL were included, of whom 31 (17.7%) were HIV-positive. The median survival time was 36 months (IQR: 21–49). The estimated 5-year OS was 25%. Advanced disease (stage IV; AHR = 2.7, 95% CI: 1.1–6.5), HIV-positive status (AHR = 2.3, 95% CI: 1.1–5.0), elevated serum lactate dehydrogenase (LDH) (≥2× upper limit of normal; AHR = 2.2, 95% CI: 1.0–4.9), and delayed initiation of chemotherapy (≥2 months; AHR = 2.6, 95% CI: 1.2–5.8) were independently associated with increased mortality. Among HIV-positive patients, neutropenic fever was the sole independent predictor of death (AHR = 4.3, 95% CI: 1.1–17.4). Conclusions: Survival among patients with DLBCL in Northwest Ethiopia remains poor, particularly among those presenting with advanced disease, those living with HIV, those that have delayed treatment initiation, and those that have elevated serum LDH – all these parameters were independently associated with increased mortality. Strengthening diagnostic capacity, ensuring equitable access to immunochemotherapy, integrating HIV–oncology services, and prioritizing early treatment initiation are essential to improving outcome.

5 March 2026 in Therapeutic Advances in Infectious Disease
Verified
Journal Article
Open access
woretaw  sisayworetaw sisay
woretaw sisay
MAMuluken Adela Alemu
Muluken Adela Alemu
TMTilaye Arega Moges
Tilaye Arega Moges
SASisay Sitotaw Anberbr
Sisay Sitotaw Anberbr
DMDesalegn Addis Mussie
Desalegn Addis Mussie
SDSamuel Berihun Dagnew
Samuel Berihun Dagnew
Background: Despite prophylactic pharmacotherapy being ranked as the best intervention yet, poor treatment adherence tempers tuberculosis preventive therapy (TPT) efficacy. Objectives: This study aimed to investigate TPT non-adherence among household contacts and its determinants following the rollout of the 3HP regimen in northwest Ethiopia. Design: A facility-based multicenter retrospective study was conducted in selected hospitals of northwest Ethiopia from October 17 to February 21, 2024. Methods: Target populations were TPT-eligible household contacts (⩽15 years old) based on the national tuberculosis treatment guideline. Univariate and multivariate binary logistic regression model was fitted to identify potential predictors. p -Value < 0.05 was employed to adjudicate the significance level. Results: Among 494 household contacts (HHCs) enrolled in this study, 27.94% were non-adherent. Age (5–10 years: adjusted odds ratio (AOR) (95% CI): 1.92 (1.05–3.19); 10–15 years: AOR (95% CI): 2.04 (1.01–4.12)), parental status (AOR (95% CI): 1.87 (1.02–5.24)), comorbidity (AOR (95% CI): 2.92 (1.08–5.69)), poor nutritional status (AOR (95% CI): 1.30 (1.06–2.43)), adverse drug reactions (AOR (95% CI): 4.01 (1.03–8.20)), adherence support (AOR (95% CI): 1.56 (1.08–6.69)) and TPT regimen type (AOR (95% CI): 4.23 (1.85–6.53)) predicts non-adherence. Conclusion: Altogether, this study revealed a high level of non-adherence among HHCs in northwest Ethiopia, falling short of the national 2025/26 TPT targets. TPT should be accompanied by firm counseling and routine supervision to improve adherence.

12 August 2026 in BMJ Paediatrics Open
Verified
Journal Article
Open access
PDF file
AKAbel Temeche Kassaw
Abel Temeche Kassaw
GTGetachew Yitayew Tarekegn
Getachew Yitayew Tarekegn
DMDesalegn Addis Mussie
Desalegn Addis Mussie
SWSamuel Agegnew Wondm
Samuel Agegnew Wondm
TMTilaye Arega Moges
Tilaye Arega Moges
TZTigabu Eskeziya Zerihun
Tigabu Eskeziya Zerihun
Background: Early-onset sepsis (EOS) is a leading cause of neonatal morbidity and mortality and contributes substantially to empirical antibiotic use in neonatal intensive care units (NICUs). In low-resource settings, limited diagnostic capacity often results in overtreatment, increasing unnecessary antibiotic exposure and its associated risks. Evidence on context-adapted EOS risk assessment pathways in sub-Saharan Africa remains scarce. Objective: To evaluate the impact of implementing an adapted EOS risk assessment pathway on antibiotic use and clinical outcomes among neonates admitted to NICUs in Northwest Ethiopia. Method: A prospective multicentre quasi experimental pre-post-implementation study was conducted in three tertiary NICUs in Northwest Ethiopia from January to April 2026. A total of 412 neonates aged ≤72 hours and born at ≥34 weeks’ gestation with suspected EOS were included (pre-implementation, n=208; post-implementation, n=204). An adapted EOS risk assessment and antimicrobial stewardship pathway was implemented during the post-implementation phase. Differences between groups were assessed using χ², Fisher’s exact, independent t or Mann–Whitney U tests, as appropriate. Logistic regression and Cox regression were used to evaluate empirical antibiotic use and 28-day mortality, respectively. Statistical significance was declared at p<0.05. Results: Maternal and neonatal characteristics were similar between study phases. Empirical antibiotics intuition decreased from 80.8% to 55.4% (risk ratio (RR)=0.69, 95% CI 0.60 to 0.80; p5 days) decreased from 40.8% to 18.1% (RR=0.44, 95% CI 0.31 to 0.62; p=0.004), antibiotic discontinuation within 48 hours increased from 8.2% to 15.7% (RR=1.90, 95% CI 1.1=3.34; p=0.02). Complete blood count, C-reactive protein and blood culture testing also decreased (all p<0.001), and mean NICU safety was shorter after implementation (8.9±2.9 vs 8.1±2.5 days; p=0.002). In multivariable analysis, implementation of the EOS pathway was associated with lower odds of empirical antibiotic use (adjusted OR 0.29, 95% CI 0.19 to 0.46). No significant adverse clinical outcomes difference between study phases. 28-day mortality did not differ between groups (15.9% vs. 17.2%; p=0.7). Conclusions: Implementation of an adapted EOS risk assessments and stewardship pathway significantly reduced unnecessary antibiotic exposure and laboratory testing without observed increase in adverse clinical outcomes. These findings support the use of structured EOS risk assessment to improve antibiotic stewardship in NICU in resource-limiting settings.

25 April 2026 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
GYGetachew Yitayew
Getachew Yitayew
ETEndalemaw Tsegaw
Endalemaw Tsegaw
FDFisseha Nigussie Dagnew
Fisseha Nigussie Dagnew
SASisay Sitotaw Anberbr
Sisay Sitotaw Anberbr
TMTilaye Arega Moges
Tilaye Arega Moges
DMDesalegn Addis Mussie
Desalegn Addis Mussie
Adverse drug reactions (ADRs) are an important and potentially preventable cause of morbidity among hospitalized obstetric patients, with implications for both maternal and fetal safety, yet evidence from low‐resource settings remains limited. This prospective observational study, conducted from February to May 2025 at Debre Tabor Comprehensive Specialized Hospital, Ethiopia, aimed to determine the magnitude, characteristics, preventability, and determinants of ADRs among hospitalized pregnant women and postpartum women within six weeks of delivery. ADRs were identified through daily chart review and patient interviews and confirmed using the Naranjo Adverse Drug Reaction Probability Scale, while severity and preventability were assessed using the modified Hartwig and Siegel scale and the Schumock and Thornton criteria, respectively. Multivariate logistic regression was used to identify factors independently associated with ADR occurrence. Among the 354 patients included, 52 experienced at least one ADR, yielding a prevalence of 14.7%. Most ADRs were mild to severe (88.5%) and classified as definitely preventable (82.7%). Polypharmacy (4–6 medications) was independently associated with ADR occurrence (adjusted odds ratio [AOR] = 4.02; 95% CI: 1.63–9.93). Additionally, patients with a history of adverse pregnancy outcomes (AOR = 6.28; 95% CI: 2.64–14.95) and those with underlying medical comorbidities (AOR = 2.95; 95% CI: 2.23–9.76) had significantly higher odds of experiencing ADRs. ADRs were relatively common among hospitalized obstetric patients, and the predominance of preventable events highlights the need for strengthened pharmacovigilance systems and targeted medication safety interventions to reduce preventable harm and improve maternal and fetal outcomes in resource‐limited settings.